Number of the records: 1
Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines
- 1.
SYSNO ASEP 0346747 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines Author(s) Reiniš, Milan (UMG-J) RID
Štěpánek, Ivan (UMG-J) RID
Šímová, Jana (UMG-J) RID
Bieblová, Jana (UMG-J)
Přibylová, Hana (UMG-J)
Indrová, Marie (UMG-J) RID
Bubeník, Jan (UMG-J)Source Title International Journal of Oncology. - : Spandidos Publications - ISSN 1019-6439
Roč. 36, č. 3 (2010), s. 545-551Number of pages 7 s. Language eng - English Country GR - Greece Keywords MHC class I-deficient tumours ; CpG oligodeoxynucleotides ; human papilloma virus Subject RIV EB - Genetics ; Molecular Biology R&D Projects IAA500520605 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR) IAA500520807 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR) CEZ AV0Z50520514 - UMG-J (2005-2011) UT WOS 000274718400003 DOI 10.3892/ijo_00000528 Annotation We investigated the efficacy of peptide and peptide-pulsed dendritic cell-based vaccines in a murine model of experimental MHC class I-deficient tumours (TC-1/A9), expressing E6/E7 oncogenes derived from HPV16. Peptide vaccine based on the “short” peptide E749-57 harbouring the CTL epitope and co-administered to the C57BL/6 mice with CpG oligodeoxynucleotide as adjuvant effective against MHC class I-positive but not –deficient tumours, while the “longer” peptide E744-62 (harbouring CTL and Th epitopes)-based vaccines were effective against MHC class I-deficient tumours. Further, we investigated the efficacy of dendritic cells pulsed with either E749-57 or E744-62 peptides. Treatment with dendritic cells pulsed with a “short” peptide resulted in the tumour growth inhibition, albeit weaker as compared to the immunisation with the longer peptide-containing DC. Our data demonstrate that cell-based vaccines can be designed to elicit immunity against MHC class I-deficient tumours. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2011
Number of the records: 1